Sun Pharma's US innovative drug sales surpass generics for first time

Sun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on medicines. The company is evaluating its current footprint and considering localization options, though the tariff's impact on its product portfolio remains uncertain. Sun Pharma also confirmed upcoming launches and R&D investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7qIJbws
via IFTTT